argenx SE (ARGNF)

Market Cap	45.56B +17.8%
Revenue (ttm)	4.25B +89.0%
Net Income	1.29B +55.1%
EPS	19.57 +53.1%
Shares Out	n/a
PE Ratio	35.26
Forward PE	26.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	29
Open	814.94
Previous Close	794.60
Day's Range	814.94 - 814.94
52-Week Range	532.40 - 872.27
Beta	-0.18
RSI	61.03
Earnings Date	Feb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,599
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARGNF

Financial Performance

In 2025, argenx SE's revenue was $4.25 billion, an increase of 88.95% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.